Compare BioNano Genomics Inc (BNGO) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs New York Times Co — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while New York Times Co trades at $73.2 (market cap $11.81B). The key difference: New York Times Co is far larger — about 894.7× BioNano Genomics Inc's market cap, and New York Times Co pays a 1.26% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | NYT | |
|---|---|---|
Market Cap | $13.20M | $11.81B |
Sector | Health | Media |
52-Week High | $4.92 | $85.86 |
52-Week Low | $1.09 | $51.43 |
Enterprise Value | $15.81M | $11.21B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
The New York Times (NYT) stock trades at $75.04, up 0.11% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company shows strong fundamentals with revenue growth from $2.3B in 2022 to $2.8B in 2025 and net income margin improving to 12.17%. Recent earnings beats and a 29.41% analyst buy rating support positive sentiment, though legal and regulatory pressures from ongoing subpoenas and copyright disputes with OpenAI present near-term risks.
Outlook remains cautiously optimistic with a consensus price target of $78.00, offering ~4% upside. Investment opportunities include consistent earnings growth and defensive stock characteristics amid market volatility. Key risks involve legal overhangs from government subpoenas and AI copyright litigation, which could impact operational focus and financial performance if prolonged.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
